Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novavax Inc Publishes Positive Preclinical Efficacy Data Against Influenza A(H7N9)


Monday, 29 Jul 2013 07:52am EDT 

Novavax, Inc. announced positive preclinical data for the Company's virus-like particle (VLP) vaccine candidate against A(H7N9) influenza. The data were published online in the peer reviewed journal Vaccine. The study examined the immunogenicity and efficacy of two doses of its A(H7N9) VLP vaccine candidate against a lethal wild-type challenge mouse model. Three control groups included Novavax' non-homologous A(H7N3) VLP vaccine candidate, its A(H5N1) VLP vaccine candidate, and a placebo. All vaccine candidates were administered with or without Iscomatrix, a saponin-based adjuvant. 

Company Quote

5.94
-0.03 -0.50%
22 Dec 2014